Group B Streptococcus: global incidence and vaccine development.
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
Johri
Atul Kumar
AK
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India. akjohri14@yahoo.com
Paoletti
Lawrence C
LC
Glaser
Philippe
P
Dua
Meenakshi
M
Sharma
Puja Kumari
PK
Grandi
Guido
G
Rappuoli
Rino
R
D016667:Bacterial Capsules / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D005260:Female; D015964:Gene Expression Regulation, Bacterial / Q000276:immunology; D016680:Genome, Bacterial / Q000276:immunology; D014943:Global Health; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D011135:Polysaccharides, Bacterial / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000517:prevention & control; D040901:Proteomics; D013290:Streptococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity
D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial